Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, and Immunotherapy and Immune Responses.
A targetable developmental program co-regulates angiogenesis and immune evasion in melanoma.
Lymphatic egress recycles tumor-experienced effector CD8 T cells to sustain immune surveillance
Impact of racial and ethnic background on overall survival in endometrial cancer patients receiving immunotherapy as front-line treatment
Chromatin architecture and physical constriction cooperate in phenotype switching and cancer cell dissemination
Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma
Integrated in vivo functional screens and multiomics analyses identify α-2,3-sialylation as essential for melanoma maintenance
Integrated in vivo functional screens and multiomics analyses identify α-2,3-sialylation as essential for melanoma maintenance.
NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma.
Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors.
Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.
Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening.
Data from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
Figure S5 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
Supplementary Table S1 from Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors
Figure S2 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Figure 2 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Figure S1 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
Table S10 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
Supplementary Table S3 from Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors
Data from Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors
Supplementary Figure S8 from Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors
Supplementary Figure S6 from Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors
Table S2 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
Table S8 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
Table S12 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
Supplementary Figure S12 from Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors
Figure S3 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Data from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Figure 4 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Table S5 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening